Mon | Jan 19, 2026

Extra COVID vaccine OK’d for those with weak immune systems

Published:Friday | August 13, 2021 | 9:24 AM
In this January 15, 2021, file photo, Dr Yomaris Pena, internal medicine physician with Somos Community Care extracts the Pfizer COVID-19 vaccine out of a vial at a vaccination site at the Corsi Houses in the East Harlem neighborhood of New York. US health regulators have authorised extra doses of the COVID-19 vaccines in people with weakened immune systems to better protect them from the virus. (AP Photo/Mary Altaffer, File)

WASHINGTON (AP) — United States regulators say transplant recipients and others with severely weakened immune systems can get an extra dose of the Pfizer or Moderna COVID-19 vaccines to better protect them as the delta variant continues to surge.

The late-night announcement Thursday by the Food and Drug Administration applies to several million Americans who are especially vulnerable because of organ transplants, certain cancers or other disorders.

Several other countries, including France and Israel, have similar recommendations.

It's harder for vaccines to rev up an immune system suppressed by certain medications and diseases, so those patients don't always get the same protection as otherwise healthy people — and small studies suggest for at least some, an extra dose may be the solution.

“Today's action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19,” Dr Janet Woodcock, the FDA's acting commissioner, said in a statement.

The FDA determined that transplant recipients and others with a similar level of compromised immunity can receive a third dose of the vaccines from Pfizer and Moderna at least 28 days after getting their second shot.

The FDA made no mention of immune-compromised patients who received the single-dose Johnson & Johnson vaccine.

The announcement comes as the extra-contagious delta version of the coronavirus surges through much of the country, pushing new cases, hospitalisations and deaths to heights not seen since last winter.

Importantly, the FDA's decision only applies to this high-risk group, estimated to be no more than 3% of U.S. adults.

It's not an opening for booster doses for the general population.

Instead, health authorities consider the extra dose part of the initial prescription for the immune-compromised. 

Follow The Gleaner on Twitter and Instagram @JamaicaGleaner and on Facebook @GleanerJamaica. Send us a message on WhatsApp at 1-876-499-0169 or email us at onlinefeedback@gleanerjm.com or editors@gleanerjm.com.